Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection

被引：46

作者：

Jagu, Subhashini ^{[1
]}

Kwak, Kihyuck ^{[1
]}

Garcea, Robert L. ^{[2
]}

Roden, Richard B. S. ^{[1
,3
,4
]}

机构：

[1] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21231 USA

[2] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA

[3] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21231 USA

[4] Johns Hopkins Univ, Dept Gynecol & Obstet, Baltimore, MD 21231 USA

来源：

VACCINE | 2010年 / 28卷 / 28期

基金：

美国国家卫生研究院;

关键词：

Human papillomavirus; L1; VLP; Capsomeres; Capsomers; L2; Multimeric; VIRUS-LIKE PARTICLES; HUMAN-PAPILLOMAVIRUS TYPE-16; IMMUNOSTIMULATORY PHOSPHOROTHIOATE OLIGONUCLEOTIDE; CAPSID PROTEIN; SUSTAINED EFFICACY; YOUNG-WOMEN; IMMUNIZATION; IMMUNOGENICITY; NEUTRALIZATION; VACCINES;

D O I：

10.1016/j.vaccine.2010.04.039

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Immunization with L1 as pentavalent capsomeres or virus-like particles (VLPs) generates high and long-lived titers of neutralizing antibodies and protection primarily against the human papillomavirus (HPV) type from which the vaccine was derived. Conversely, vaccination with 12 minor capsid protein derived from multiple HPV types induces lower titer, but more broadly neutralizing and protective antibody responses. We combined the advantages of each protective antigen by immunization with titrated doses of multi-type L2 with either L1 capsomeres or VLP. We observed no significant interference between the L1 and L2 antibody response upon co-administration of L1 vaccines with multi-type L2 vaccines. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：4478 / 4486

页数：9

共 46 条

[41] A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response [J].

Thoenes, Nadja ;

Herreiner, Anna ;

Schaedlich, Lysann ;

Piuko, Konrad ;

Mueller, Martin .

JOURNAL OF VIROLOGY, 2008, 82 (11) :5472-5485

[42] Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes [J].

Thoenes, Nadja ;

Mueller, Martin .

VIROLOGY, 2007, 369 (02) :375-388

[43] High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up [J].

Villa, L. L. ;

Costa, R. L. R. ;

Petta, C. A. ;

Andrade, R. P. ;

Paavonen, J. ;

Iversen, O-E ;

Olsson, S-E ;

Hoye, J. ;

Steinwall, M. ;

Riis-Johannessen, G. ;

Andersson-Ellstrom, A. ;

Elfgren, K. ;

von Krogh, G. ;

Lehtinen, M. ;

Malm, C. ;

Tamms, G. M. ;

Giacoletti, K. ;

Lupinacci, L. ;

Railkar, R. ;

Taddeo, F. J. ;

Bryan, J. ;

Esser, M. T. ;

Sings, H. L. ;

Saah, A. J. ;

Barr, E. .

BRITISH JOURNAL OF CANCER, 2006, 95 (11) :1459-1466

[44] Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial [J].

Villa, LL ;

Costa, RLR ;

Petta, CA ;

Andrade, RP ;

Ault, KA ;

Giuliano, AR ;

Wheeler, CM ;

Koutsky, LA ;

Malm, C ;

Lehtinen, M ;

Skjeldestad, FE ;

Olsson, SE ;

Steinwall, M ;

Brown, DR ;

Kurman, R ;

Ronnett, BM ;

Stoler, MH ;

Ferenczy, A ;

Harper, DM ;

Tamms, GM ;

Yu, J ;

Lupinacci, L ;

Railkar, R ;

Taddeo, FJ ;

Jansen, KU ;

Esser, MT ;

Sings, HL ;

Saah, AJ ;

Lupinacci, L .

LANCET ONCOLOGY, 2005, 6 (05) :271-278

[45] Immunization with a pentameric L1 fusion protein protects against papillomavirus infection [J].

Yuan, H ;

Estes, PA ;

Chen, Y ;

Newsome, J ;

Olcese, VA ;

Garcea, RL ;

Schlegel, R .

JOURNAL OF VIROLOGY, 2001, 75 (17) :7848-7853

[46] Papillomaviruses in the causation of human cancers - a brief historical account [J].

zur Hausen, Harald .

VIROLOGY, 2009, 384 (02) :260-265

← 1 2 3 4 5 →